• Record sales order momentum maintained, supporting medium-term revenue visibility
• Timing impacts on revenue conversion, including MEG installation delays and Somfit D rollout
• Cost discipline and improved scale help offset timing delays, supporting earnings resilience

Compumedics continues to deliver solid underlying operating performance, with strong order intake across its core platforms. The current year-to-date result reflects timing differences between order intake and revenue recognition, particularly in capital equipment and MEG, rather than any deterioration in underlying demand. Revenue conversion has been slower than anticipated, reflecting MEG shipment and installation timing, supply chain constraints including helium availability and pricing pressures, and a later Somfit D rollout in the US due to a deliberate focus on manufacturing readiness and quality of deployment. Despite these timing-related impacts, Compumedics' EBITDA performance remains resilient, supported by active cost management, a US cost base reset, and the benefit of higher revenue scale. The company's Sleep and Neurology business continues to show stable to improving performance across most regions, with ongoing growth in connected platforms and expanding SaaS and annuity revenue streams. The Orion LifeSpan MEG business remains a high-value growth platform, with strong underlying demand, though revenue timing has been impacted by installation scheduling and helium-related issues. Compumedics maintains a strong liquidity position, supported by material MEG cash receipts and expanded banking facilities. The company has updated its FY26 guidance to reflect the timing-related impacts, with revenue expected to be approximately $62 million to $65 million and EBITDA approximately $5.5 million to $7 million. Despite these timing-related impacts, Compumedics remains confident in the strength of its underlying demand environment, its technology and product portfolio, and its positioning for improved growth and earnings in FY27.

Revenue: approximately $62 million to $65 million, representing approximately 22% to 28% growth on FY25 EBITDA: approximately $5.5 million to $7 million

Compumedics continues to expect further strong growth through FY27, supported by conversion of the existing order book, commercialisation and scaling of Somfit D, and continued growth in SaaS and recurring revenue streams.